Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > The issue of the safe use of higher doses of vaccinia virus
View:
Post by Noteable on Jul 15, 2022 11:05am

The issue of the safe use of higher doses of vaccinia virus

https://www.biospace.com/article/releases/siga-announces-oncology-collaboration-with-kalivir-immunotherapeuticssiga-to-supply-tpoxx-to-support-kalivir-s-oncolytic-vaccinia-clinical-immunotherapy-program/
Comment by m00nsh0ts on Jul 15, 2022 7:28pm
What issue? Also, do you know, was this the virus used in the car T study that didn't seem to work as a booster? tia
Comment by Noteable on Jul 16, 2022 5:19pm
The issue of the safe use of higher doses of vaccina virus is described in collaboration announcement of Signa Technologies and Kalivir Immunotherapeutics for Signa's drug TPOXX, which is a powerful antiviral drug to vaccinia. The collaboration's purpose is to work towards achieving the safe use of vaccinia virus (VV) vectors at higher doses and to bring levels of assurance to physicians ...more  
Comment by Noteable on Jul 18, 2022 11:50am
Virus Safe Handling Content from the - Environmental Health and Safety -  BioSafety Manual - University of Florida Poxvirus (Vaccinia): Poxviruses are double-stranded, enveloped DNA viruses belonging to poxvirus family. The viruses provide an excellent tool for recombinant DNA technology due to their large genome size capable of accommodating large inserts, up to 25Kb, and their ability for ...more  
Comment by Noteable on Jul 29, 2022 12:34pm
July 28, 2022  - Takeda is walking away from the vaccinia virus cancer prospect it picked up in a $120 million deal frome Turnstone Biologics in 2019. Citing “strategic reasons,” the company has terminated the collaboration and returned the global rights for the asset to Turnstone. In a separate decision to discontinue their collaboration Takeda explicitly referred to " ...more  
Comment by Noteable on Jul 29, 2022 12:43pm
Correction:  - Takeda is walking away from a 2019 bio-buck deal with Turnstone Biologics, that included a $120 million up-front payment for Turnstone's vaccinia virus cancer prospect. 
Comment by canadafan on Jul 29, 2022 1:19pm
One thing we know 100% certain, oncolytics Pelareorep is 100% safe. that & systemic i.V. Administration gives Pela a huge competitive advantage. speaking about the recent Goblet results  imagine a cancer therapy that does shrink tumours & next to zero side effects. many existing "chemotherapy" drugs may work, but the side issues can be very hard on the body. back to ...more  
Comment by Noteable on Jul 21, 2023 10:56am
July 21, 2023 - Turnstone Biologics closes $80 million IPO. The San Diego-based company has already set how it plans to use the money to fund phase 1 work on its lead asset TIDAL-01 for breast and colorectal cancers as well as move another tumor-infiltrating lymphocyte into the clinic and run combination trials with viral immunotherapies. In July 2022  Takeda walked away from the ...more  
Comment by Noteable on Jul 21, 2023 11:03am
" That same IPO paperwork shed more light on the end of Turnstone’s deal with AbbVie, which paid $90 million to work with the biotech in 2017 but terminated the partnership in 2021. A separate $80 million upfront development deal with Takeda only lasted until 2022 with a remaining discovery pact with the Japanese Big Pharma ending in 2023. Against that backdrop, Turnstone’s IPO is a ...more  
Comment by Noteable on Jul 21, 2023 11:18am
https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-strengthens-senior-management-and-clinical The OV company Genelux's primary product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV)
Comment by Noteable on Jul 21, 2023 11:57am
Vaccina Virus (smallpox virus) is a DNA virus and not an RNA virus like ONCY's pelareorep. Two Republican lawmakers in Idaho intended to criminalize the use of all RNA viruses across the state. "Misinformed individuals have gained political power and are currently trying to use their positions to advance agendas that will limit citizens choices," said Dr. Daniel Griffin, chief of ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities